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Functional map of arrestin binding 
to phosphorylated opsin, with and 
without agonist
Christian Peterhans1, Ciara C.M. Lally2, Martin K. Ostermaier2, Martha E. Sommer2 & 
Jörg Standfuss1
Arrestins desensitize G protein-coupled receptors (GPCRs) and act as mediators of signalling. Here 
we investigated the interactions of arrestin-1 with two functionally distinct forms of the dim-light 
photoreceptor rhodopsin. Using unbiased scanning mutagenesis we probed the individual contribution 
of each arrestin residue to the interaction with the phosphorylated apo-receptor (Ops-P) and the 
agonist-bound form (Meta II-P). Disruption of the polar core or displacement of the C-tail strengthened 
binding to both receptor forms. In contrast, mutations of phosphate-binding residues (phosphosensors) 
suggest the phosphorylated receptor C-terminus binds arrestin differently for Meta II-P and Ops-P. 
Likewise, mutations within the inter-domain interface, variations in the receptor-binding loops and 
the C-edge of arrestin reveal different binding modes. In summary, our results indicate that arrestin-1 
binding to Meta II-P and Ops-P is similarly dependent on arrestin activation, although the complexes 
formed with these two receptor forms are structurally distinct.
GPCRs mediate cellular signalling networks and regulate a wide variety of physiological and sensory responses. 
GPCRs are highly abundant in higher eukaryotes, especially in mammals, and approximately 1000 individual 
GPCR genes are known1,2. GPCR dysfunction and misfolding give rise to many diseases, and over 60% of pre-
scribed drugs act on GPCRs3. The large and diverse GPCR superfamily is regulated by a small family of geneti-
cally and structurally conserved arrestin proteins. Arrestin-1 and -4 are solely expressed in photoreceptor neuron 
cells, whereas the two β -arrestins (arrestin-2 and -3) are ubiquitously expressed4. Arrestins both suppress G 
protein-mediated signalling as well as mediate their own signalling networks by scaffolding other signalling pro-
teins. Recent studies report that different receptor phosphorylation patterns give rise to different conformations 
of arrestin, which are associated with different cellular functions5,6. The ability of different GPCR ligands to selec-
tively elicit G protein-mediated or arrestin-mediated signalling, a phenomenon termed biased signalling, has 
been a topic of intense study and speculation7,8.
Structurally arrestins are composed of cup-shaped N- and C-domains and a long, flexible, auto-inhibitory 
C-tail. In the basal state, the C-tail is anchored to the N-domain by hydrophobic interactions within the 3-element 
interaction and by hydrogen bonding within the polar core. Activation of arrestin is triggered by binding to the 
active state of the receptor or the phosphorylated receptor C-terminus (Rpp). Based on mutagenesis studies9,10 
(summarized in11) and the crystal structures of pre-activated arrestins12,13, the mechanism of arrestin activa-
tion is as follows: Binding of Rpp to phosphate-binding residues (phosphosensors) on β -strand I in the arrestin 
N-domain breaks the 3-element interaction, which releases the arrestin C-tail and thereby breaks the polar core. 
The displacement of the C-tail has widespread effects on the arrestin structure. The two domains of arrestin rotate 
against each other by ~20° and several loops in the central crest region are mobilized for receptor binding. The 
recent crystal structure of the complex of constitutively active human opsin fused to constitutively active mouse 
arrestin-1 (Ops*/arrestin-1) illustrates how these conformational changes facilitate coupling of arrestin to the 
helical bundle of the active receptor14.
This study focuses on arrestin-1, the rod visual arrestin, and its interactions with different functional forms 
of the GPCR rhodopsin. Rhodopsin consists of the apo-protein opsin and the Schiff base-linked inverse agonist 
11-cis retinal. Light triggers isomerization of the ligand to the agonist all-trans retinal, which leads to formation of 
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the active receptor species Metarhodopsin II (Meta II). Meta II couples to and activates the G protein transducin 
and is also phosphorylated by GPCR kinase-1 (GRK1), which enables arrestin binding15–18. About one minute 
after light-activation, phosphorylated Metarhodopsin II (Meta II-P) decays to opsin: the retinal Schiff base link-
age spontaneously hydrolyses, and retinal exits the ligand binding pocket19. In its phosphorylated form, opsin is 
still bound by arrestin, and regeneration of the receptor with 11-cis-retinal is likely required to fully dissociate 
arrestin20–22. The interaction of arrestin with phosphorylated opsin (Ops-P) is functionally important, both to 
quench the residual activity of opsin, as well as to protect the rod cell in bright light by stimulating uptake of toxic 
all-trans-retinal into the pool of opsin23–25. Genetic pathologies that alter binding of arrestin-1 can lead to reduced 
vision by Oguchi disease26, congenital stationary night blindness27,28 or retinitis pigmentosa29.
Here we assess the functional contribution of each residue in arrestin-1 to binding of Ops-P, in comparison 
to Meta II-P. We used native rod outer segment (ROS) membranes, which preserve natural receptor density and 
phosphorylation patterns. Our results indicate both similarities and differences in how arrestin binds the two 
receptor forms. Site-directed fluorescence experiments suggest that some of these similarities, such as engage-
ment of the finger loop, are due to the ability of Ops-P to adopt an active conformation similar to Meta II-P. 
Importantly, differences between the functional maps reflect different binding modes, which are distinct with 
respect to how the phosphorylated receptor C-terminus is bound within the arrestin N-domain, the extent of 
interdomain rotation, and deployment of the C-edge.
Results
Scanning mutagenesis of arrestin-1 and generation of functional maps for binding to Meta II-P 
and Ops-P. We applied alanine scanning mutagenesis on arrestin-1 to identify and compare the contribu-
tions of all side-chains in binding Meta II-P and Ops-P. Every residue in the arrestin-1 sequence, except the first 
methionine, was mutated to alanine, and native alanine residues were mutated to glycine9,30. Arrestin mutants 
were cloned in-frame with the fluorescent protein mCherry and expressed in E. coli. The fluorescence of mCherry 
facilitated the detection of the expression level and was used as an easy read-out to quantify the amount of arres-
tin pulled-down by ROS membranes in a high-throughput manner. The relative binding affinity of the arrestin 
mutants was assayed using titration of NaCl as multisite inhibitor (Fig. 1a). Mutations that increase or decrease 
binding strength resulted in higher or lower half maximum inhibitory concentrations of sodium chloride (IC50) 
compared to wild-type, respectively (Fig. 1b). We have previously established this experimental approach in order 
to generate a functional map of arrestin-1-binding to Meta II-P9.
Figure 1. Quantification of arrestin mutants and calculation of IC50 values. Each alanine-mutant was 
expressed in E. coli and used for centrifugal pull-down analysis with native ROS membranes containing Meta 
II-P or Ops-P. Light-activated Meta II-P was assayed in parallel and simultaneously with the apo-form Ops-P. 
(a) NaCl titrations against arrestin-1 wild-type (WT) binding to Meta II-P (red) or Ops-P (blue) were used 
to calculate sigmoidal dose-response curves and extract IC50 values. (b) Distribution of IC50 values for the 
complete arrestin functional map when bound to phosphorylated Meta II-P (red) and Ops-P (blue). The dashed 
line indicates the WT IC50 values, and dotted lines indicate the doubled standard deviation calculated from 
arrestin WT data sets.
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Here we investigated arrestin-1 binding to highly phosphorylated opsin, Ops-P. ROS membranes were isolated 
from bovine retina and rhodopsin phosphorylation was carried out using the endogenous GRK1 according to a 
protocol that is optimized for high phosphorylation levels22. The phosphorylation level of ROS membranes was 
evaluated using arrestin-dependent Meta II-P stabilisation (Fig. 2). We prepared a single large batch of Ops-P, 
half of which was regenerated with 11-cis-retinal to form phosphorylated rhodopsin for the light-dependent 
formation of Meta II-P. Binding to Ops-P and Meta II-P were measured in parallel. In this way we generated two 
distinct functional maps of arrestin-1 binding to Ops-P and Meta II-P, which can be directly compared to one 
another.
The IC50 value derived from NaCl titration against wild-type arrestin binding to Meta II-P was determined in 
40 independent measurements over the course of several months to be 0.59 ± 0.04 M, which is similar to previ-
ously reported values9,22,31 (Fig. 1a). This value is ~44% higher than that reported in our previous arrestin alanine 
scan study9, and we believe this difference is due to higher levels of receptor phosphorylation in the current study. 
We found that arrestin-1 binding to Ops-P was much more salt sensitive than Meta II-P binding (7-fold reduced 
IC50, 0.076 ± 0.004 M), which is consistent with previous reports18,22 (Fig. 1a). Salt titrations and pull-downs were 
performed for each arrestin-1 mutant, and wild-type was expressed and processed in parallel for each batch (see 
Methods). The dataset for Ops-P is 91% complete. Some mutants had to be rejected from the analysis due to poor 
expression or insufficient interaction with Ops-P membranes. For Meta II-P, the dataset is complete to 89%. A 
complete list of all IC50 values for Meta II-P and Ops-P can be found as Supplementary Table 1 information.
We mapped the contributions of all side chains onto the arrestin structure32, using different colouring to 
indicate whether mutations increased or decreased binding strength (Fig. 3b,c). For both Ops-P and Meta II-P, 
mutations affecting binding strength positively as well as negatively are spread over the whole arrestin sequence 
(Fig. 3b,c), although many of the mutants with strong effects are clustered. 25% of tested residues outside the 
double standard deviation threshold are positively correlated, i.e. had the same general effect in both Ops-P and 
Meta II-P (Figs 1b and 3d). However, a similar number (24%) of residues are present as distinct clusters of nega-
tively correlated residues (Fig. 3e). More information about calculation and ranking of IC50 values can be found 
in Methods.
Functional map similarities. The polar core is a buried hydrogen bond network composed of residues 
from both the N- and C-domains, as well as the C-tail (D30, R175, D296, D303, T304, R382), which stabilises the 
basal state of arrestin13,32. Nearly all mutations in the polar core strongly increased binding to both Meta II-P and 
Ops-P (Table 1). The 3-element interaction also controls the arrestin activation state and involves hydrophobic 
side-chain interactions between β -strand I, α -helix I and the C-tail of arrestin (H10, V11, I12, F13, L107 L111, 
F375, V376, F377, F380)33. Disruption of the 3-element interaction and the release of the arrestin C-tail is crucial 
for arrestin activation and exposes a stretch of positively charged residues involved in Rpp binding9,12,34. Nearly all 
mutations within the 3-element interaction increased IC50 values for both Meta II-P and Ops-P binding (Table 1).
The finger loop (G68–S78) is a flexible loop in the arrestin central crest that is a critical receptor-binding 
element. Two recent crystal structures indicate that this loop binds in a near-helical conformation deep in the 
cytoplasmic crevice of the active receptor14,35. In our mutagenesis analysis, mutations in the finger loop decreased 
affinity to both Meta II-P and Ops-P (Table 1 and Fig. 3b–d). Residues 73, 74, 75, 77, 78 have low IC50 values 
for Meta II-P. For Ops-P residues 71, 73, 74, 76, 77, 78, 79 have weak binding when mutated. Similar to the 
Figure 2. Functional test of receptor phosphorylation. The “Extra Meta II” assay measures the stabilisation 
of Meta II (λ max: 380 nm) over its precursor Meta I (λ max: 480 nm) by absorbance spectroscopy. In the absence 
of any binding partner, very little Meta II evolved (black trace). In the presence of the high-affinity analogue 
peptide derived from the C-terminus of the α -subunit of transducin (Gtα -peptide, VLEDLKSCGLF, 350 μ M), 
100% of receptors were stabilised as Meta II (blue trace). In the presence of arrestin (10 μ M), all receptors were 
also stabilised as Meta II (red trace). Hence, all receptors in our preparation were sufficiently phosphorylated 
to bind arrestin as Meta II-P. A high level of receptor phosphorylation is indicated by the fast rate of arrestin 
binding, which is comparable to Gtα -peptide. This assay has previously been established as an indicator of 
functional receptor phosphorylation for studies of arrestin binding22.
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finger loop, mutations on the 160-loop (H155–P165) generally decreased affinity to both Meta II-P and Ops-P 
(Fig. 3b–d).
We were surprised to observe the importance of the finger loop for arrestin-1 binding to Ops-P, consider-
ing previous studies indicated that this loop is only engaged by the active receptor22,36–39. Thus we further char-
acterized the interaction of Ops-P membranes with an arrestin-1 mutant labelled on the finger loop with the 
environmentally sensitive fluorophore N,N′-dimethyl-N-(iodoacetyl)-N′-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
ethylenediamine (NBD). The fluorescence of the labelled arrestin mutant (I72NBD) increases dramatically when 
Table 1.  Selection of IC50 values in functionally important regions of arrestin-1.
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the finger loop is buried in the hydrophobic crevice of the active receptor40. Using an excess of receptor, we 
observed that Ops-P at pH 7 induced a fluorescence increase ~45% as great as that of arrestin I72NBD bound 
to Meta II-P (Fig. 4a). Interestingly, at pH 6 arrestin I72NBD binding to Ops-P resulted in a fluorescence signal 
comparable to that induced by Meta II-P. In contrast, arrestin binding to Ops-P at pH 8 resulted in a fluorescence 
increase only ~18% as great as Meta II-P. Centrifugal pull-down analysis employing the same samples described 
above indicated that all arrestin was membrane-bound in each case (Fig. 4b). Hence, the observed pH-dependent 
differences in I72NBD fluorescence in the presence of OpsP was not due to different levels of arrestin binding. 
We additionally examined the interaction of Ops-P with the arrestin mutant I299B/L173W, which is labelled 
with a bimane fluorophore on the gate loop (residues 296–305). In the basal unbound state, the gate loop of 
arrestin forms part of the intact polar core, and this mutant exhibits an enhanced fluorescence due to site 299 
being buried by the C-tail. Upon arrestin binding to Meta II-P, the C-tail is displaced and the gate loop moves 
toward the N-domain, which brings site 299 into close proximity with the tryptophan residue at site 17313. This 
Figure 3. Functional maps of arrestin-1 binding to Meta II-P and Ops-P. (a) Important functional regions 
highlighted on the basal arrestin structure32. (b) IC50 values for Meta II-P binding plotted on the basal structure 
of arrestin-1. Mutations which significantly increased or decreased binding are coloured green and purple, 
respectively. (c) IC50 values for Ops-P binding. Colour code follows that described in (a). (d) Positive correlation 
of mutants for Meta II-P and Ops-P binding. Green – mutations which increased binding for both Meta II-P 
and Ops-P. Orange – mutations which decreased binding for both Meta II-P and Ops-P. (e) Negative correlation 
of mutants for Meta II-P and Ops-P binding. Yellow – mutations which increased affinity for Meta II-P but 
decreased affinity for Ops-P. Pink – mutations which decreased affinity for Meta II-P but increased affinity for 
Ops-P. For (b–e), only IC50 values outside the doubled standard deviation are shown.
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conformational change results in a significant quenching of the bimane fluorescence. Notably, this mutant is 
sensitive to the activation state of the receptor, and we previously reported that gate loop movement only occurs 
upon arrestin-1 coupling to Meta II-P and not inactive Ops-P13. In the present study, we observed that an excess 
of Ops-P at pH 7 induced gate loop movement in ~57% of the arrestin I299B/L173W (Fig. 4c). Similar to arrestin 
I72NBD, pH 6 favoured an Ops-P-dependent fluorescence change similar to that induced by Meta II-P, and pH 8 
reduced the intensity of the fluorescence change to ~38% that of Meta II-P. Centrifugal pull-down analysis again 
confirmed that these differences in fluorescence were not due to different levels of arrestin binding (Fig. 4d). 
Together these results indicate that, depending on the pH, arrestin employs different binding modes when engag-
ing Ops-P, which are distinct with respect to the finger and gate loops. In the Discussion we further elaborate on 
the molecular basis of these different binding modes, and the implications for understanding the functional maps.
Functional map differences. Disruption of the 3-element interaction by mutation increased IC50 values 
for both Meta II-P and Ops-P binding. Interestingly alanine substitution of the bulky phenylalanine residues at 
sites 375 and 377, the main anchors of the C-tail, had a more dramatic effect on Ops-P compared to Meta II-P 
binding (~2.9-fold increase versus ~1.4-fold increase in IC50). Likewise, truncation of the arrestin C-tail (1–378, 
Δ 379–404) had a more positive effect on Ops-P binding (4-fold increase in IC50) than Meta II-P binding (1.4-fold 
increase in IC50).
The N-domain of arrestin harbours many basic residues that could serve as phosphosensors, many of which 
have been implicated by mutagenesis9,41 and X-ray protein crystallography12,13. Conservation of identified phos-
phosensors in the different arrestin subtypes, especially arrestin-1 and arrestin-2, and their engagement in bind-
ing to conserved phosphorylation sites in different GPCR C-tails has been reviewed8. Direct comparison of the 
IC50 values for mutants of these potential phosphosensing sites reveals strikingly different patterns for Ops-P and 
Meta II-P binding (Table 1 and Fig. 5). Whereas K14 and K15 are important for both receptor forms, mutation of 
K5, K20, R29, K110, K300 and H301 most strongly affected Meta II-P binding. These sites line a positively charge 
cleft within the N-domain, which is exposed upon displacement of the C-tail. On the other hand Ops-P binding is 
was most affected by mutation of residues H10, R18, K55, R56, R81, K150, K166 and R171. These sites are mostly 
localized within the cup of the N-domain.
Figure 4. Site-directed fluorescence. (a) Steady-state fluorescence spectra of arrestin I72NBD (1 μ M) were 
measured in the absence (grey trace) or presence of an excess of receptor (6 μ M): light-activated Meta II-P at 
pH 7 (dashed black trace), Ops-P at pH 6 (red trace), Ops-P at pH 7 (green trace) or OpsP at pH 8 (blue trace). 
(b) Centrifugal pull-down analysis of arrestin I72NBD binding to Meta II-P at pH 7 (lane 1) or Ops-P at pH 6, 
7 or 8 (lanes 2, 3 and 4, respectively). As a negative control, no pull down of arrestin with Ops-P at pH 7 in the 
presence of 1 M NaCl was observed (lane 5). The total amount of arrestin in each pull-down experiment (4.5 μ g) 
is shown in lane 6. The arrows indicate the location of arrestin (Arr) and receptor (R). (c) Same as described in 
(a), performed with arrestin I299B/L173W. (d) Same as described in (b), performed with arrestin I299B/L173W. 
Note that these experiments were performed in low-salt buffer in order to maximize arrestin binding to OpsP.
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Several negatively correlated residues for Meta II-P and Ops-P binding in the arrestin N-domain reveal the 
differential engagement of phosphosensors (Fig. 3e). Significant clusters of negatively correlated residues are 
also present within the inter-domain interface and the C-edge. The inter-domain interface undergoes signifi-
cant rearrangements upon arrestin activation, resulting in a ~20° twist of the arrestin C-domain relative to the 
N-domain12,13. Clusters of negatively correlated residues within the inter-domain interface include region 209–
220 (Loop 12–13 near the inter-domain hinge), and region 310–324 (part of Loop17–18, which winds between 
the two domains of arrestin) (Table 1 and Fig. 3e). Notably, these areas are rearranged in pre-activated arrestin 
p44 as compared to basal arrestin-1. The root-mean-square deviation (RMSD) between basal and pre-activated 
Figure 5. Different engagement of phosphosensors. Phosphosensing residues, whose mutation strongly 
decreased binding are highlighted in blue in (a) and (b) on pre-activated arrestin p4413. (a) Phosphosensitive 
residues deployed by Meta II-P (K14, K15, K20, R29, K110, K300 and H301) are located along the side of the 
arrestin N-domain. Side view (left) and top view (right) of arrestin are shown. The top view represents the 
orientation of arrestin as seen from the cytoplasmic face of the receptor. (b) Phosphosensing residues deployed 
by Ops-P (K14, K15, R18, K55, R56, R81, K150, K166, R171 and K300) are located in the cup of the arrestin 
N-domain. Views of arrestin are as in (a). (c) The phosphosensitive residues (blue) determined from the Meta 
II-P functional map are plotted on the Ops* /arrestin-1 complex14. The receptor is cyan, and the dashed line 
indicates the membrane plane. (d) The receptor phosphopeptide (Rpp) (mint green) aligned on arrestin. The 
Rpp model is adapted from9. N326, shown as sticks, is the last resolved residue in14 and is also shown as sticks in 
the Rpp model.
www.nature.com/scientificreports/
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arrestin p44 for region 209–220 is ~3.2 Å, and the RMSD for region 310–324 is ~4.6 Å. The rearrangements in 
these regions are directly related to the inter-domain rotation that accompanies arrestin activation13,32.
Besides the inter-domain interface, negatively correlated residues are clustered within the C-edge, specifically 
near the 270-loop (residues 268–274) and the 344-loop (residues 334–338) (Table 1 and Fig. 3e). Remarkably, 
the correlation between these two regions is exactly opposite: mutations within region 268–274 enhanced Meta 
II-P binding and decreased Ops-P binding, while mutations within 334–338 decreased Meta II-P binding and 
enhanced Ops-P binding. Similarly, mutations in the middle loop generally increased binding to Ops-P but had 
mixed effects on Meta-II. Mutations of residues 81–84 just adjacent to the finger loop region, on the other hand, 
increased affinity to Meta II-P but decreased affinity to Ops-P (Supplementary Table 1). Altogether the data thus 
indicates structurally similar but distinct binding modes of the two receptor forms.
Structural context of functional maps. The first crystal structure of a GPCR in complex with arres-
tin was recently published14. This breakthrough was possible by fusing a constitutively active mutant form of 
human rhodopsin to both lysozyme (to facilitate crystallisation) and a constitutively active mutant form of mouse 
arrestin-1 (to favour arrestin binding to the receptor). The agonist all-trans-retinal is not resolved, yet the com-
plex adopts an active conformation (Ops* ) due to the activating mutations, presence of detergent, and low pH. 
The receptor-bound arrestin displays all the hallmarks of arrestin activation12,13, including displacement of the 
C-tail, breakage of the polar core, inter-domain rotation, and significant rearrangements of the central crest loops 
(e.g. finger, middle, C-loops).
Arrestin makes several specific contacts with the receptor in the Ops* /arrestin-1 complex, and mutation of 
these contact points are expected to affect binding affinity. We analysed these binding interactions using the pro-
gram EPPIC (Evolutionary Protein-Protein Interaction Classifier), which detects the core interacting residues in a 
complex and evaluates biocompatibility of the interface based on evolutionary conservation42. The computational 
analysis confirmed the interaction interface to be biologically relevant. Moreover, when our mutagenesis data for 
Meta II-P and Ops-P binding are plotted on the structure of the complex, it is clear how mutations in core inter-
acting regions would interfere with coupling to the active receptor (Fig. 6).
Firstly, the finger loop is deeply inserted into the central cavity formed upon activation of the receptor. 
Mutation of several residues in the finger loop resulted in low IC50 values for Meta II-P (Fig. 6b), and Ops-P 
(Fig. 6c) binding. Differences in the mutation patterns are likely due to variations in engagement of the receptor 
(see Discussion), however weak binding of finger loop mutations on both Meta II-P and Ops-P reflects the biolog-
ical relevance of finger loop interaction with the receptor.
Figure 6. Mutational data on the Ops*/arrestin-1 complex structure. (a) Model derived from the arrestin-
receptor complex structure14, rhodopsin (cyan), and arrestin (grey). Finger, middle and C-loop are coloured 
like in Fig. 3. Dashed lines indicate the membrane bilayer. (b) Arrestin-rhodopsin interaction coloured by IC50 
values derived by Meta II-P interaction. (c) Arrestin-rhodopsin interaction coloured by IC50 values derived 
by Ops-P interaction. In (b,c), the receptor-arrestin interaction, coloured according to mutations which 
significantly increased (green) or decreased (purple) binding for Ops-P (colour code follows that from Fig. 3b,c). 
Core interaction residues as classified by EPPIC are shown as sticks42. Top panels in (b,c) show the interaction 
with loop 160, finger, middle and C-loop. Bottom panels show putative membrane interaction sites in the 
C-edge loops.
www.nature.com/scientificreports/
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Secondly, the 160-loop of arrestin contacts transmembrane helix 6 of the receptor, specifically via a hydrogen 
bond between D162 (D163 in mouse arrestin-1) and K245 on the receptor. Residues 161–163 are classified as rim 
residues by the program EPPIC. Rim amino acids directly interact with the receptor albeit their buried surface 
area is smaller than core residues. In agreement with this structural analysis, mutation of E161, D162 and K163 
significantly decreases Meta II-P binding. The effect of the mutations is less pronounced in case of Ops-P, where 
D162 even resulted in slightly increased binding.
Thirdly, the C-loop within the central crest of arrestin makes hydrophobic contacts with intracellular loop 
(ICL2) of the receptor, which adopts a helical conformation. The importance of the contact point is reflected in 
the functional map of Meta II-P binding, where mutations in the C-loops lead to significantly reduced IC50 values.
The final contact point identified in the Ops* /arrestin-1 structure actually does not involve the receptor. The 
arrestin in the complex is bound to the receptor at an angle such that the 344-loop within the C-edge would be 
expected to interact with the membrane (although loop-344 is not completely resolved in the structure, and 
no membrane is present). Notably, mutation of several sites on the C-edge within the 344-loop and the nearby 
200-loop significantly decrease binding to Meta II-P. Most of the influential mutations are hydrophobic or 
uncharged amino acids (e.g. L338, L339, L342, S345, F197, M198, S199), suggesting a possible role in interacting 
with the hydrophobic membrane interior. In contrast, mutation of sites within the 344-loop actually increased 
binding to Ops-P. Interestingly, mutations within the 270-loop adversely affected Ops-P binding, and many of 
these sites are polar or charged amino acids (e.g. E263, Q265, K267, N271). These differences suggest different 
roles for the C-edge loops in Meta II-P and Ops-P binding. Furthermore, the placement of the 344-loop within 
the putative membrane plane of the Ops* /arrestin-1 complex is supported by Meta II-P functional map.
Overall, we surmise that the Meta II-P functional data are most consistent with the Ops* /arrestin-1 complex 
structure, which would be compatible with the constitutively active state of the receptor in this complex.
Discussion
This study was initiated based on the hypothesis that arrestin-1 employs different binding modes for Meta II-P 
and Ops-P22. The functional maps we present here indicate both similarities and differences regarding how 
arrestin-1 interacts with these two physiologically important forms of the receptor. In general the results demon-
strate the structural and functional versatility that is common to all arrestin family members.
The similarities in the functional maps we observed can be partially explained by the presence of active-state 
opsin in the pull-down experiments using Ops-P. In the native membrane, opsin exists in a pH-dependent con-
formational equilibrium between inactive opsin (Ops), which resembles dark-state rhodopsin, and active opsin 
(Ops* ), which structurally resembles Meta II-P43–47. Vogel et al. reported a pK of the Ops/Ops* equilibrium of ~4, 
meaning that essentially no Ops* exists in native membranes at physiological pH. However, we surmise that 
Figure 7. Interaction of arrestin with different functional forms of the receptor. (a) Cartoon representation 
of arrestin in the basal state. Notable loops include the finger loop (blue), the gate loop (yellow) and the 160-loop 
(black). The C-tail of arrestin is dark orange and interacts with the N-domain through the 3-element interaction 
and the polar core. (b) Dark state rhodopsin (Rho, red) and basal arrestin. (c) Light activation converts 
rhodopsin to Meta II, which is phosphorylated on the C-terminus by GRK1 and then bound by arrestin. 
Hallmarks of high affinity binding include receptor engagement of the finger loop and 160-loop, inter-domain 
rotation, and movement of the gate loop, which allows the phosphorylated receptor C-terminus to bind within 
a positively charged cleft in the N-domain. (d,e) Meta II-P decays to the apo-receptor Ops-P, which exists in a 
conformational equilibrium between an active (Ops* ) and inactive (Ops) form. Arrestin binds Ops* -P similarly 
as Meta II-P. The interaction of arrestin with inactive Ops-P differs in the placement of the finger loop, the 
phosphorylated receptor C-terminus and how the C-edge is engaged.
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receptor phosphorylation shifts the equilibrium toward Ops* , given that phosphorylation stabilises the active 
Meta II-P species over its inactive precursor Meta I48. The binding of arrestin would additionally influence the 
amount of receptor stabilised as Ops* -P22. For the current study, we estimated how much Ops-P could be sta-
bilized in the active form by arrestin. In order to do this, we used fluorescently labelled arrestin mutants that 
report two key aspects of arrestin binding to the active receptor: finger loop engagement (I72NBD) and gate loop 
movement (I299B/L173W) (Fig. 4a,c). We used a six-fold excess of receptor to arrestin, which is a reasonable 
approximation of the conditions used in the pull-downs employing arrestin-mCherry mutants (see Methods). 
The fluorescence data indicate that about half of the 1 μ M arrestin was bound to the active receptor form Ops* -P 
at pH 7, since the fluorescence signal obtained with Ops-P at pH 7 was about half as great as that obtained with 
Meta II-P (Fig. 4a,c). This result means that about 10% of the total opsin was stabilised as Ops* -P in complex 
with arrestin (0.5 μ M / 6 μ M = 0.083). Furthermore, we observed a pH-dependence in the fluorescence signals 
indicative of arrestin binding to the active receptor (Fig. 4a,c). Arrestin binding to Ops-P at pH 6 was similar to 
Meta II-P, and pH 8 significantly decreased the amount of Ops-P bound in the active form. Given that Ops* -P 
is favoured at lower pH values43, these observations suggest arrestin binds Ops* -P similarly as Meta II-P, at 
least with regard to the finger and gate loop. Despite these similarities, Meta II-P and Ops* P binding are bio-
chemically distinct with respect to salt sensitivity. The difference can be explained by the coupling between the 
[Ops-P ↔ Ops* -P] and the [Arr + Ops* -P ↔ Arr● Ops* -P] equilibria. This coupling lowers the apparent affinity 
of arrestin for Ops* -P, because the conformational equilibrium of the receptor is heavily shifted toward inactive 
Ops-P in the native membrane. The fluorescence experiments presented here suggest that arrestin binding shifts 
the receptor conformational equilibrium by stabilizing Ops* -P (Fig. 7).
Based on the fluorescence experiments, we conclude that our functional map of Ops-P binding represents a 
combination of Ops-P and Ops* -P characteristics. The complex of arrestin with Ops* -P is structurally very sim-
ilar to that with Meta II-P. In contrast, arrestin binding to inactive Ops-P is primarily electrostatic, and the finger 
loop is not engaged nor is the gate loop displaced (Fig. 7)13,18,22. Here we discuss the similarities and differences 
between the functional maps, keeping in mind the findings from the fluorescence experiments. We attempt to 
differentiate between arrestin elements important for binding inactive Ops-P and active Ops* -P.
The Meta II-P and Ops-P functional maps are very similar with respect to the key structural elements con-
trolling phosphorylation-dependent arrestin activation: the polar core and the C-tail. These two elements sta-
bilise the inactive, basal state of arrestin and their disruption by mutagenesis has long been known to lead to 
constitutive activity in arrestin31,32,49,50. Recent crystal structures of C-terminally truncated arrestin13,51 and the 
R175E arrestin mutant52 indicate how these mutations structurally activate arrestin for receptor binding. Alanine 
substitutions in the polar core or 3-element interaction increased arrestin binding to both Meta II-P and Ops-P. 
These mutations pre-activate arrestin and lower the energy barrier for coupling to the active receptor53. Hence, 
we hypothesize that pre-activated mutants are able to stabilize Ops* -P to a greater extent, which would explain 
the striking similarities between the Meta II-P and Ops-P functional maps for the polar core and 3-element 
interaction.
Interestingly, mutations which displaced the C-tail increased affinity for Ops-P to a greater extent than Meta 
II-P. These mutations included alanine substitution of the bulky hydrophobic residues involved in anchoring 
the C-tail within the 3-element interaction (F375 and F377), and C-tail truncation. C-tail displacement exposes 
a large area of electropositive surface within the arrestin N-domain13,51. Given the fact that arrestin binding to 
Ops-P is primarily electrostatic and heavily dependent on the level of receptor phosphorylation, it is not sur-
prising that C-tail displacement would dramatically increase affinity for Ops-P18,22. A similar effect is observed 
for p44, a naturally occurring splice variant of arrestin-1 that lacks the C-tail, which has significantly enhanced 
affinity for all forms of phosphorylated rhodopsin, even inactive dark-state rhodopsin and Ops-P10.
Meta II-P and Ops-P binding were both negatively affected by mutations in the finger loop and 160-loop, 
which engage the active receptor in the Ops* /arrestin-1 complex14, this similarity could suggest a common bind-
ing mode, although it is also possible that these loops engage Meta II-P and Ops-P differently. Both of these 
loops are intrinsically very flexible and adopt a variety of conformations, or are not visible in the many crystal 
structures of arrestin13,32,51,54–56. Notably, the positioning of the finger loop in the Ops* /arrestin-1 complex and the 
complex of Ops* with a peptide analogue of the finger loop are different14,35. This difference could be simply due 
to the different structural constraints (free peptide versus loop anchored to the body of arrestin) or the mutations 
introduced into opsin in the Ops* /arrestin-1 complex. Yet it is also possible that the flexible finger loop can adopt 
a variety of conformations within the cytoplasmic crevice of the active receptor, which is supported by DEER 
studies of arrestin-1 binding to rhodopsin57. Different finger loop binding modes for Meta II-P (or Ops* -P) 
and Ops-P could also be implied by the opposite mutagenesis patterns seen in the residues 81–84, adjacent to the 
finger loop region.
Despite the many similarities between the Meta II-P and Ops-P functional maps, we detected significant dif-
ferences that could indicate distinct binding modes. Firstly, the mutation of potential phosphosensors within the 
arrestin N-domain, in the region where the phosphopeptide derived from the V2 vasopressin receptor interacts 
with arrestin-212 had dramatically distinct effects on Meta II-P and Ops-P binding13,41. A plot of affected resi-
dues on the arrestin surface yields distinct “phosphosensing footprints” for Meta II-P and Ops-P (Fig. 5). Meta 
II-P binding was most negatively affected by mutation of residues which line the positively-charged cleft within 
the N-domain, which is exposed upon full displacement of the C-tail12,13. In contrast, Ops-P binding was most 
affected by mutation of residues within the cup of the N-domain. Surprisingly, mutation of these residues had 
exactly the opposite effect on Meta II-P binding. This difference indicates that these residues are playing different 
roles in Ops-P and Meta II-P binding. In the case of Ops-P, we hypothesize that these residues bind Rpp. In the 
case of Meta II-P, these residues are in close proximity to the cytoplasmic face of the receptor, and their mutation 
would make the N-domain cup more electronegative. This change would increase binding affinity to Meta II-P, 
since the cytoplasmic face of the receptor is strongly electropositive14.
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Overall these results indicate that Rpp binds arrestin differently for Meta II-P and Ops-P. We believe the 
arrestin-2/V2Rpp structure12 is similar to how Rpp binds in the arrestin/Meta II-P complex, although some dif-
ferences likely exist because of the different phosphorylation patterns between the V2R and rhodopsin8. Distinct 
receptor phosphorylation patterns, which arise from ligand bias and/or GPCR C-tail subtype, are believed to 
engage specific clusters of phosphosensors and thereby direct the cellular functions of arrestin5,6,8. However, here 
we observe different phosphosensor engagement, depending on the presence or absence of agonist for the same 
Rpp phosphorylation pattern. In contrast to the arrestin/Meta II-P complex, we speculate that Rpp binds within 
the cup of the N-domain in the arrestin-1/Ops-P complex (Fig. 5). These different modes in Rpp binding are 
supported by site-directed fluorescence experiments, which indicated that the arrestin gate loop is displaced from 
its basal position only in complex with Meta II-P22. Movement of the gate loop is necessary for Rpp to access the 
positively-charged cleft within the N-domain. It is interesting to note the correlation between the mutation pat-
terns in our functional maps and the different phosphorylation requirements of Meta II-P and Ops-P binding. 
Only four residues (K5, K14, R29, H301) strongly affected Meta II-P binding, which corresponds well to two to 
three phosphates that are required for maximal Meta II-P binding17,18. In contrast, nine residues strongly affected 
Ops-P binding (belong to the group of the lowest 20%), which mirrors the dependence of Ops-P binding on high 
levels of receptor phosphorylation18,22.
The Meta II-P and Ops-P functional maps are also distinct with respect to the inter-domain interface. For 
example, mutation of residues within region 310–324 of Loop17–18, increased Ops-P binding and weakened 
Meta II-P binding. Most of the critical sites are aliphatic residues (e.g. I311, G315, I316, I323, L324) that are 
solvent-exposed in the basal state structure and more buried in the pre-active p44 structure13. We hypothe-
size that mutation of these residues may interfere with the hydrophobic packing necessary to stabilise the new 
inter-domain orientation of the arrestin active state. Hence, the inter-domain rotation seen in the pre-active arres-
tin structures might be more critical for Meta II-P binding, and Ops-P binding might be different in this respect.
The rearrangement of the inter-domain interface causes a rotation of the two domains of arrestin against one 
another. In the Ops* /arrestin-1 complex structure14 the asymmetric binding of arrestin to the receptor, along with 
the twist of the C-domain, positions the loops of the C-edge within or near the theoretical plane of the membrane 
adjacent to the receptor. Previous site-directed fluorescence studies suggested the C-edge might interact with the 
membrane, or another receptor in a one-to-two complex22. Intriguingly, we observed strong changes in IC50 val-
ues, both positive and negative, when side chains in the C-edge were removed by alanine substitution. Strong and 
weak binders are clustered in a directly reversed manner between Meta II-P and Ops-P. Although the function 
of the C-edge is currently not well understood, the different patterns seen between Meta II-P and Ops-P binding 
could reflect distinct modes in membrane binding or different receptor binding stoichiometries. Considering 
the orientation of the C-edge is controlled by the extent of inter-domain rotation, it is likely that the positive and 
negative correlations seen in the inter-domain interface and in the C-edge are related and reflect distinct binding 
modes employed by arrestin for Ops-P and Meta II-P.
Conclusions and Outlook
The functional maps we present here indicate both similarities and differences in how arrestin binds the phospho-
rylated apo-receptor Ops-P and the phosphorylated agonist-activated receptor Meta II-P.
To date rhodopsin is the only GPCR for which we have a crystal structure in complex with arrestin. 
Determination of this structure was only possible through heavy engineering of both rhodopsin and arrestin, 
which could significantly alter the complex. Our functional maps were obtained under physiological conditions 
and in a native membrane environment. The Meta II-P functional map confirms the core interaction sites seen in 
the structure and indicates how the phosphorylated receptor C-terminus, which is absent in the structure, binds 
arrestin. Importantly, comparison of the Meta II-P and Ops-P functional maps indicates a versatility in the way 
that GPCRs are bound by arrestin. Arrestins have a variety of functions, including desensitization of G protein 
signalling, receptor internalization and arrestin-mediated signalling. The known modulators of these arrestin 
functions, such as biased agonists that stabilize different active receptor conformations or stimulate different 
receptor phosphorylation patterns, could reasonably result in different conformations of receptor-bound arrestin 
and/or different receptor binding modes. Scanning mutagenesis may provide a way to isolate the functional foot-
prints that orchestrate the complexity of GPCR and arrestin signalling.
Methods
Receptor preparations. Rod outer segment disc membranes (ROS) were isolated from frozen bovine retina 
(W.K. Lawson Company, USA), and phosphorylation was carried out using the native rhodopsin kinase present 
in the ROS, exactly as previously described22. Receptor phosphorylation was quenched with 20 mM hydrox-
ylamine, and subsequent washes removed the hydroxylamine and peripheral ROS proteins (e.g. native arres-
tin). Phosphorylated rhodopsin (Rho-P) was prepared by the addition of a 3-fold molar excess of 11-cis-retinal 
to Ops-P under dim red light. The 11-cis-retinal was generated from commercially available all-trans-retinal 
(Sigma-Aldrich) and purified by high-pressure liquid chromatography. For the current study, a single large-scale 
preparation of Ops-P and Rho-P was made from 400 retinas (total yield of 240 mg of receptor), so that all arrestin 
mutants were tested using the same batch of phosphorylated ROS. The phosphorylation level of the preparation 
was assessed by the Extra Meta II assay, which is described in detail elsewhere22,40.
Arrestin expression and cell lysate preparation. Detailed information concerning the constructs used 
in this study has been previously presented9,30. In brief, bovine arrestin-1 (SAG) was cloned into the “EgWoMiPi” 
vector suitable for mammalian and bacterial expression. The fluorescent protein “mCherry” was connected by 
a short linker sequence (GSSG) and a TEV protease cleavage site (ENLYFQGS) to the C-terminal part of the 
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expression cassette. Mutations were introduced by site-directed PCR using the program AAscan30. Mutant con-
struct plasmids were used to transform chemically competent E.coli BL21(DE3) cells (Stratagene). Transformed 
cells were grown as previously described9. Briefly, cells were grown at 37 °C, and expression of arrestin-mCherry 
was induced by 100 μ M IPTG at an OD of 0.6. Expression in 200 mL LB medium was carried out at 20 °C for 
18 h. Wild-type arrestin was always expressed alongside the mutants for each data set. Cells were harvested by 
centrifugation, and pellets were frozen in liquid nitrogen and stored at -80 °C. Frozen cell pellets were thawed on 
ice and resuspended in 1.8 mL of lysis buffer (10 mM HEPES pH 7.0, 10 mM NaCl, 0.1 mM EDTA, 5 mM DTT) 
containing protease inhibitor cocktail (Roche) and PMSF. For cell lysates destined for pull-down experiments 
using Ops-P, lysis buffer additionally contained 5 mM hydroxylamine and 10 mM NaCl. For cell lysates destined 
for pull-down experiments using Meta II-P, lysis buffer additionally contained 1 mM MgCl2, and 100 mM NaCl. 
Lysozyme (0.2 mg/mL) and DNAase (20 μ g/mL) were added to the resuspended cells, which were lysed by soni-
cation. The lysate was cleared by centrifugation (13800 × g, 90 min, 4 °C).
Centrifugal pull-down assay. Cell lysate containing expressed arrestins-mCherry fusion proteins were 
assayed similarly as before9. Briefly, arrestin mutants and wild-type control were analysed in parallel using a 
96-well centrifugal pull-down assay. For each arrestin construct, cleared cell lysate containing arrestin-mCherry 
(800 μ L) was mixed with ROS membranes (100 μ l) containing 135 μ g of Ops-P or phosphorylated rhodopsin. This 
“mastermix” was divided into 8 wells (100 μ l each) on a 96-well plate. The wells were pre-loaded with 100 μ L of 
buffer containing increasing NaCl concentrations. Final NaCl concentrations for Meta II-P pull-downs were 50, 
159, 249, 450, 707, 999, 1600, 2500 mM and final NaCl concentrations for Ops-P pull-downs were 4.4, 24, 54, 79, 
104, 154, 304, 1504 mM. The final concentration of receptor was 1.85 μ M and the final concentration of arrestin 
was estimated at 0.1–0.6 μ M based on mCherry fluorescence. Plates were incubated at 37 °C for 2 min and then 
illuminated with bright light and immediately centrifuged at 6168 × g for 20 min at 4 °C. The membrane pellets 
were washed two times with buffer.
Fluorescent mCherry detection and dose-response curve fitting. Washed membrane pellets were 
resupended in 100 μ L buffer (10 mM HEPES pH 7.0, 10 mM NaCl, 0.1 mM EDTA, 5 mM DTT). Buffer for Meta 
II-P samples additionally contained 1 mM MgCl2 and 100 mM NaCl. Samples were transferred to new plates 
for fluorescence detection, and mCherry fluorescence was measured using a microplate reader (λ ex = 488 nm, 
λ em = 612 nm). Fluorescence signals were normalised for each mutant, such that the highest signal equalled 
100%. Dose-response curve fitting was performed with GraphPad Prism using a symmetrical sigmoidal dis-
tribution with variable slope (four-parameter dose response fit) using constraints for top and bottom values 
[Y = Bottom + (Top − Bottom)/(1 + 10^((LogIC50-X)* HillSlope))]. Half-maximum inhibitory concentrations 
(IC50) were thus obtained for all mutants for Ops-P and Meta II-P binding.
Analysis of IC50 values. For the two datasets derived from Ops-P and Meta II-P binding, IC50 values were 
sorted from top to bottom for the entire dataset. Mutant IC50 values inside the double-standard deviation calcu-
lated from 40 wild-type measurements were not considered significantly different than wild-type and have been 
rejected from analysis. The significant values were grouped and ranked according to top 20%, top 30%, low 30%, 
and low 20% within the sorted datasets. The functional maps were generated by plotting the ranked residues onto 
the arrestin structure using distinct colouring for top and low IC50 values (Fig. 3b,c). Mutations which resulted 
in significantly higher or lower IC50 values for both Ops-P and Meta II-P binding were considered positively 
correlated. Mutations which resulted in a high IC50 value for one dataset and a low IC50 value for the other were 
considered negatively correlated. Positive and negative correlations were also plotted onto the arrestin structure 
(Fig. 3d,e).
Site-directed fluorescence experiments. Recombinant bovine arrestin-1 mutants (C63A, C128S, 
C143A, W194F, I72C and C63A, C128S, C143A, W194F, L173W, I299C) were expressed and purified from E. coli 
as previously described58. The I72C mutant was labelled with IANBD, and the L173W/I299C mutant was labelled 
with monobromobimane (fluorophores purchased from ThermoFisher Scientific), and steady-state fluorescence 
was measured using a SPEX Fluorolog (1680) instrument as reported before40. The NBD fluorophore was excited 
at 500 nm, and the bimane fluorophore was excited at 390 nm. In general, the fluorescence of 1 μ M labelled arres-
tin mutant was measured in the absence or presence of a six-fold excess of Rho-P or Ops-P at 20 °C. Rho-P was 
converted to Meta II-P using bright light (> 495 nm, 10 s), and the fluorescence of the labelled arrestin was meas-
ured immediately after light-activation of the sample. Samples were suspended in 50 mM HEPES at pH 6, 7, or 8. 
Fluorescence spectra were plotted and analysed in the graphing program Sigma Plot, and the spectra in Fig. 4 are 
normalized to the spectrum of unbound arrestin. Complementary pull-down experiments using identical sam-
ples used for fluorescence experiments were performed as described13. After centrifugation, membrane pellets 
were solubilized in SDS loading buffer and subjected to SDS-PAGE (12%). Gels were stained with Coomassie 
brilliant blue, destained, and imaged using a scanning device.
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